tetano
Editor, Senior Moderator
Tex Heart Inst J
. 2021 Nov 1;48(5):e207446.
doi: 10.14503/THIJ-20-7446.
Atypical ST-Segment-Elevation Myocardial Infarction Presentation in Patients With COVID-19 at a High-Volume Center in New York City
Miguel A Alvarez Villela[SUP] 1 [/SUP], Ahmad Alkhalil[SUP] 1 [/SUP], Michael A Weinreich[SUP] 1 [/SUP], Jonathan Koslowsky[SUP] 1 [/SUP], Shunsuke Aoi[SUP] 1 [/SUP], M Azeem Latib[SUP] 1 [/SUP]
Affiliations
Abstract
Atypical presentations of ST-segment-elevation myocardial infarction (STEMI) have been reported in patients who have COVID-19. We have seen this occurrence in our center in Bronx, New York, where multitudes of patients sought treatment for the coronavirus. We studied the prevalence of atypical STEMI findings among patients with COVID-19 who presented during the first 2 months of the pandemic. Consistent with previous reports, 4 of our 10 patients with COVID-19 and STEMI had no identifiable culprit coronary lesion; rather, they often had diffuse ST-segment elevations on surface electrocardiograms along with higher levels of D-dimer and inflammatory markers. In contrast, 32 of 33 patients without COVID-19 (97%) had a culprit lesion. The patients with COVID-19 and a culprit lesion more often needed thrombectomy catheterization and administration of glycoprotein IIb/IIIa inhibitors. Our study confirms that patients with COVID-19 often have atypical STEMI presentations, including the frequent absence of a culprit coronary lesion. Our findings can help clinicians prepare for these atypical clinical presentations.
Keywords: COVID-19; Cardiovascular diseases/physiopathology; ST elevation myocardial infarction/complications/epidemiology; coronary angiography; coronavirus infections/diagnosis; retrospective studies; time-to-treatment.
. 2021 Nov 1;48(5):e207446.
doi: 10.14503/THIJ-20-7446.
Atypical ST-Segment-Elevation Myocardial Infarction Presentation in Patients With COVID-19 at a High-Volume Center in New York City
Miguel A Alvarez Villela[SUP] 1 [/SUP], Ahmad Alkhalil[SUP] 1 [/SUP], Michael A Weinreich[SUP] 1 [/SUP], Jonathan Koslowsky[SUP] 1 [/SUP], Shunsuke Aoi[SUP] 1 [/SUP], M Azeem Latib[SUP] 1 [/SUP]
Affiliations
- PMID: 34913970
- DOI: 10.14503/THIJ-20-7446
Abstract
Atypical presentations of ST-segment-elevation myocardial infarction (STEMI) have been reported in patients who have COVID-19. We have seen this occurrence in our center in Bronx, New York, where multitudes of patients sought treatment for the coronavirus. We studied the prevalence of atypical STEMI findings among patients with COVID-19 who presented during the first 2 months of the pandemic. Consistent with previous reports, 4 of our 10 patients with COVID-19 and STEMI had no identifiable culprit coronary lesion; rather, they often had diffuse ST-segment elevations on surface electrocardiograms along with higher levels of D-dimer and inflammatory markers. In contrast, 32 of 33 patients without COVID-19 (97%) had a culprit lesion. The patients with COVID-19 and a culprit lesion more often needed thrombectomy catheterization and administration of glycoprotein IIb/IIIa inhibitors. Our study confirms that patients with COVID-19 often have atypical STEMI presentations, including the frequent absence of a culprit coronary lesion. Our findings can help clinicians prepare for these atypical clinical presentations.
Keywords: COVID-19; Cardiovascular diseases/physiopathology; ST elevation myocardial infarction/complications/epidemiology; coronary angiography; coronavirus infections/diagnosis; retrospective studies; time-to-treatment.